RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
903. Simpson RJ Jr. Placing PRINCE in perspective. JAMA 286:91-
93, 2001
904. Shepherd J, Blauw G, Murphy M, Bollen EL, Buckley BM,
Cobbe SM y cols. Pravastatin in elderly individuals at risk of
vascular disease (PROSPER): a randomised controlled trial.
Lancet 360: 1623-1630, 2002
905. Gresser U, Gathof BS. Atorvastatin: gold standard for
prophylaxis of myocardial ischemia and stroke comparison
of the clinical benefit of statins on the basis of randomized
controlled endpoint studies. Eur J Med Res 9: 1-17, 2004.
906. Nissen S, Tuzcu E, Schoenhagen P, Brown BG, Ganz P, Vogel
RA, y cols. Effect of intensive compared with moderate lipid
lowering therapy on progression of coronary atherosclerosis:
a randomized controlled trial. JAMA 291: 1071-1080, 2004
907. Cannon CP, Braunwald E, Mc Cabe, Rader DJ, Rouleau JL,
Belder R y cols. Intensive versus moderate lipid lowering
with statins after acute coronary syndromes. N Engl J Med
350: 1495-1504, 2004.
908. Athyros V, Elisaf M, Papageorgiou A, Symeonidis AN,
Pehlivanidis AN, Bouloukos VI, y cols. Effect of statins versus
untreated dyslipidemia on serum uric acid levels in patients
with coronary heart disease: a subgroup analysis of the
Greek atorvastatin and coronary heart disease evaluation
(GREACE) Study. Am J Kidney Dis 43: 589-599, 2004.
909. Grundy S, Cleeman J, Bairey Merz C, Brewer HB Jr, Clark LT,
Hunninghake DB y cols. Implications of recent clinical trials
for the National Cholesterol Education Program Adult
Treatment Panel III Guidelines. Circulation 110: 227-239,
2004
910. Mc Farlane SI, Muniyappa R, Francisco R, Sowers JR.
Clinical review 145: pleiotropic effects of statins, lipid
reduction and beyond. J Clin Endocrinol Metab 87: 1451-
1458, 2002
911. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles
JS, y cols. Measurement of C-reactive protein for the targeting
of statin therapy in the primary prevention of acute coronary
events. N Engl J Med 344: 1959-1965, 2001
912. Albert Ma, Danielson E, Rifai N, Ridker PM. PRINCE
Investigators: Effect of statin therapt on C-reactive protein
levels: The pravastatin inflammation/CRP evaluation (PRIN-
CE): A randomized trial and cohort study. JAMA 286: 64-70,
2001
913. Gotto AM, Farmer JA. Pleiotropic effects of statins: Do they
matter? Curr Opin Lipidol 12: 391-394, 2001
914. Munford RS. Statins and the acute phase response. N Engl J
Med 344: 2016-2018, 2001
915. Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli
G, Avellone G. Non lipid dose dependent effects pravastatin
treatment on hemostatic system and inflammatory response.
Eur J Clin Pharmacol 56: 277-248, 2000
916. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non lipid
related effects of statins. Ann Med 32: 164-176, 2000
917. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary
artery disease beyond lowering cholesterol. Ann
Pharmacother 2000; 34: 1432-1439
918. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T,
Saruta T. Fluvastatin prevents development of arterial stiffness
in haemodialysis patients with type 2 diabetes mellitus.
Nephrol Dial Transplant 17: 1513-1517, 2002
919. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F,
Bohm M. Statin sensitive dysregulated AT1 receptor function
and density in hypercholesterolemic men. Circulation 100:
2131-2134, 1999
920. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E.
Use of lipid lowering drugs and blood pressure control in
patients with arterial hypertension. J Clin Hypertens 4: 277-
285, 2002
921. Aviram M, Dankner G, Cogan O, Hochgraf E, Brook JG.
Lovastatin inhibits LDL oxidation and alters its fluidity and
uptake by macrophages, in vitro and in vivo studies.
Metabolism 41: 229-235, 1992.
922. Goppelt-Struete M, Hahn A; Iwanciw D, Rehm M, Banas B.
Regulation of connective tissue growth factor gene expression
in human mesangial cells by HMG-CoA reductase inhibitors.
Mol Pathol 54: 176-179, 2001
923. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y,
Watanabe S, y cols. Simvastatin suppresses glomerular cell
proliferation and macrophage infiltration in rats with mesangial
proliferative nephritis. J Am Soc Nephrol 9: 2027-2039,
1998
924. Grandaliano G, Biswas P, Choudhury GG, Abboud HE.
Simvastatin inhibits PDGF induced DNA synthesis in human
glomerular mesangial cells. Kidney Int 44: 503-508, 1993
925. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled,
prospective study of the effects of atorvastatin on proteinuria
and progression of kidney disease. Am J Kidney Dis 41: 565-
570, 2003
926. Sasaki T, Kurata H, Nomura, Utsunomiya K, Ikeda Y.
Amelioration of proteinuria with pravastatin in hypercholesterolemis
patients with diabetes mellitus. Jpn J Med 29. 156-
163, 1990
927. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A,
Brizzi P y cols. Additive effects of simvastatin beyond its
effects on LDL cholesterol in hypertensive type 2 diabetic
patients. Eur J Clin Invest 30: 980-987, 2000
928. Martínez-Castelao A, Ramos R, González MT, Castineiras
MJ. Dyislipidemia and cardiovascular risk in type 2 diabetes
mellitas patients with associated diabetic nephropathy.
Nefrología 22: 51-58, 2002
929. Park JK, Muller DN, Mervaala, Dechend R, Fiebeler A,
Schmidt F y cols. Cerivastatin prevents angiotensin II induced
renal injury independent of BP and cholesterol lowering
effects. Kidney Int 58: 1420-1430, 2000
930. Prasad GV, Ahmed A, Nash M, Zaltzman J. Blood pressure
reduction with HMG-CoA reductase inhibitors in renal
transplant recipients. Kidney Int 63: 360-364, 2003
931. MRC/BHF Heart Protection Study of Cholesterol lowering
with simvastatin in 5963 people with diabetes. A randomised
placebo controlled trial. Lancet 361: 2005-2016, 2003
932. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis
AN, Pehlivanidis AN, Bouloukos VI y cols. The effect of statins
versus untreated dyslipidaemia on renal function in
patients with coronary heart disease evaluation (GREACE)
study. J Clin Pathol 57: 728-734, 2004
933. Dimitriadis A, Antoniou S, Hatzisavvas N, Pastore F, Kaldi I,
Stangou M. The effect of simvastatin on dyslipemia in continous
ambulatory peritoneal dialysis patients. Periton
Dialysis Int 13: S434-S436, 1993
934. Harris KP, Wheeler DC, Chong CC. A placebo controlled
trial examining atorvastatin in dyslipidemic patients undergoing
CAPD. Kidney Int 61: 1469-1474, 2002
215